Trials / Unknown
UnknownNCT01752335
Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Hospital Universitario de Canarias · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether tocilizumab changes the cardiovascular risk factors on patients with arthritis rheumatoid. Study hypothesis: the IL-6 contributes to increase the cardiovascular risk factors of patients with rheumatoid arthritis because it produces systemic effects as increasing weight and atherogenic body fat, changing energy homeostasis and inducing the adipokines production and the insulin resistence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Braquial ecography | At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2012-12-19
- Last updated
- 2017-02-09
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01752335. Inclusion in this directory is not an endorsement.